Pharmaceuticals News and Research

RSS

Study describes relationship between gene expression and intelligence in WS patients

Although genetics is the most significant known determinant of human intelligence, how specific genes affect intelligence remains largely unknown. A multi-institution team led by a University of Utah USTAR researcher has found that the brain gene STX1A plays a significant role in the level of intelligence displayed by patients with Williams Syndrome.

23 Apr 2010

pHase Pharmaceuticals launches new drug development company

pHase Pharmaceuticals, LLC announces the launch of its new drug development company. pHase Pharmaceuticals is led by a cohesive team of drug development experts who have extensive experience bringing new drugs to market and garnering FDA approval.

23 Apr 2010

OXiGENE applies for voluntary delisting from SSE, continues to be listed on NASDAQ

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has applied for the voluntary delisting of OXiGENE common shares from the Stockholm Stock Exchange (SSE). The company will continue to be listed on the NASDAQ Global Markets exchange.

23 Apr 2010

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that it has added 170 genetically modified rats and related biomaterials to its database of laboratory rats with a genetic modification that can mimic a human disease. These animals are used by academic, pharmaceutical, and biotech scientists for drug discovery and development research and will be sold under Transposagen's new TGEM(TM) Rat Models brand.

23 Apr 2010

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted it patent number GB2460597 titled "N,N-Disubstituted aminoalkylBiPhenyl Antagonists OF Prostaglandin d2 RECEPTORS."

23 Apr 2010

Complaint regarding Dragon Pharma's proposed merger with Datong Investment filed

Dragon Pharmaceutical Inc. announced today that a complaint regarding its proposed merger with Datong Investment Inc was filed in the Circuit Court of the Fifteenth Judicial Circuit for Palm Beach County, State of Florida, against the Company, and its eight directors.

23 Apr 2010

TUM scientists collaborate with Fujitsu Laboratories of Japan to commercialize biosensor chip

In the battle against cancer and other diseases, precise analysis of specific proteins can point the way toward targeted treatments. Scientists at theTechnische Universitaet Muenchen, together with Fujitsu Laboratories of Japan, have developed a novel biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can show if these proteins are changed through the influence of disease or drugs.

23 Apr 2010

FDA rejects experimental painkiller Acurox

In a new development King Pharmaceuticals Inc. and Acura Pharmaceuticals Inc. have failed to win the approval of a US panel for marketing an experimental painkiller called Acurox.

23 Apr 2010

FDA grants tentative approval for Sagent Pharmaceuticals' adenosine injection

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration had granted tentative approval of adenosine injection, USP, the generic equivalent of Astellas Pharmaceuticals' Adenoscan®, in 60 mg per 20 mL and 90 mg per 30 mL vials. IMS data indicate that the 2009 U.S. innovator market for these adenosine presentations approximated $124 million. The Company plans to launch the product upon expiry of applicable innovator patents.

23 Apr 2010

Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that complete data from its pivotal study of Marqibo in patients with relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia, have been accepted for an oral podium presentation at the 46th Annual Meeting of the American Society of Clinical Oncology to be held June 4-8, 2010 in Chicago, Illinois.

23 Apr 2010

Colorcon acquires NP Pharm

Colorcon, Inc. today announced the acquisition of the full-service pharmaceutical excipient company, NP Pharm, a Division of Ethypharm. This acquisition expands Colorcon's global excipient product offerings in the pharmaceutical and nutritional markets.

23 Apr 2010

FDA Advisory Committees vote against approval of Acurox NDA

Acura Pharmaceuticals, Inc. and King Pharmaceuticals®, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Life Support Drugs and Drug Safety and Risk Management Committees voted that they do not have enough evidence to support the approval of the New Drug Application (NDA) for Acurox® (oxycodone HCl and niacin) Tablets for the treatment of moderate to severe pain, considering the deterrent effects of niacin as well as the potential deterrent effects of the other features specific to Acurox®.

23 Apr 2010

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC (Abstracts 3698 and 5534).

23 Apr 2010

NeoStem signs Collaborative Research Agreement with ImmuneRegen BioSciences

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China and ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced today that they have entered into a Collaborative Research Agreement, focused on the development of an advanced, adult human stem cell product.

23 Apr 2010

Biostar Pharmaceuticals lists on NASDAQ Global Market

Biostar Pharmaceuticals, Inc., a Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced that the Company was approved by NASDAQ to list its common stock on the NASDAQ Global Market. The Company's listing application was reviewed and approved by NASDAQ's Listing Qualifications Department for compliance with all of NASDAQ's standards.

23 Apr 2010

OSI Pharmaceuticals' first-quarter 2010 total revenues increase 14% to $107M

OSI Pharmaceuticals, Inc. announced today its financial results for the first quarter ended March 31, 2010. The Company reported total revenues from continuing operations of $107 million for the first quarter of 2010, a 14% increase over revenues of $94 million for the first quarter of 2009.

23 Apr 2010

Aragon Pharmaceuticals raises $22M through Series B financing

Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing.

23 Apr 2010

Ampio Pharmaceuticals signs LOI to acquire DMI Biosciences

Ampio Pharmaceuticals, Inc., today announced that it has entered into a letter of intent to acquire DMI Biosciences, Inc.

23 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Mystic Pharmaceuticals today announced it has been granted U.S. Patent 7,669,597, a key technology of its VRx2™ drug delivery platform. The VRx2™ Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.

22 Apr 2010

Pharmaceuticals News and Research

Study describes relationship between gene expression and intelligence in WS patients

pHase Pharmaceuticals launches new drug development company

OXiGENE applies for voluntary delisting from SSE, continues to be listed on NASDAQ

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

Complaint regarding Dragon Pharma's proposed merger with Datong Investment filed

TUM scientists collaborate with Fujitsu Laboratories of Japan to commercialize biosensor chip

FDA rejects experimental painkiller Acurox

FDA grants tentative approval for Sagent Pharmaceuticals' adenosine injection

Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

Colorcon acquires NP Pharm

FDA Advisory Committees vote against approval of Acurox NDA

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

NeoStem signs Collaborative Research Agreement with ImmuneRegen BioSciences

Biostar Pharmaceuticals lists on NASDAQ Global Market

OSI Pharmaceuticals' first-quarter 2010 total revenues increase 14% to $107M

Aragon Pharmaceuticals raises $22M through Series B financing

Ampio Pharmaceuticals signs LOI to acquire DMI Biosciences

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence